NorthWest Biotherapeutics Inc (NWBO)

[Astavakra]

BMS clearly would be ideal for the reasons you state. If BMS should acquire rights to DCVax-D for use in combination, in addition to the product exclusivity benefit, the revenue increase from Yervoy and Opdivo would be phenomenal.

I'm going to use these numbers just for example. I'm not making them up, but I must say in all honesty, that I haven't thoroughly researched them. That aside, sales of Opdivo by 2020 have been projected by some to be about 7B. The melanoma treatment market is projected to equal about 3.6B.
A combination therapy of Opdivo and Yervoy in the CheckMate-012 trial for lung cancer showed a reduction in tumors in 39% of patients. There's room for improvement there, for sure. If adding DCVax to the mix could boost efficacy, figure how much more valuable those two assets of BMS would become and what their revenue may be.